Purinergic P2X receptors: Structural models and analysis of ligand-target interaction

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 561-580

  Dal Ben, Diego ^a   Buccioni, Michela ^a   Lambertucci, Catia ^a   Marucci, Gabriella ^a   Thomas, Ajiroghene ^a   Volpini, Rosaria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Molecular modelling; Nucleotides; P2X receptor agonists; P2X receptor antagonists; P2X receptors; Purinergic receptors

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; 5 [[(3 PHENOXYBENZYL)(1,2,3,4 TETRAHYDRO 1 NAPHTHYL)AMINO]CARBONYL]TRIMELLITIC ACID; A 740003; A 804598; A 839977; PURINERGIC P2X RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; A-317491; ADENOSINE TRIPHOSPHATE; ANTHRAQUINONE DERIVATIVE; DICYANDIAMIDO; GUANIDINE DERIVATIVE; LIGAND; PHENOL DERIVATIVE; POLYCYCLIC HYDROCARBON; PURINERGIC P2X RECEPTOR AGONIST; PURINERGIC P2X RECEPTOR ANTAGONIST; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENDOCRINE DISEASE; HUMAN; LIGAND BINDING; MUTAGENESIS; NONHUMAN; RAT; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; STRUCTURE ACTIVITY RELATION; ZEBRA FISH;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTHRAQUINONES; AZOLES; BINDING SITES; GUANIDINES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENOLS; POLYCYCLIC COMPOUNDS; PURINERGIC P2X RECEPTOR AGONISTS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X; STRUCTURE-ACTIVITY RELATIONSHIP; ZEBRAFISH;

EID: 84908518386     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.071     Document Type: Article

References (106)

1. G. Burnstock Discovery of purinergic signalling, the initial resistance and current explosion of interest Br. J. Pharmacol. 167 2012 238 255
2. M.P. Abbracchio G. Burnstock A. Verkhratsky H. Zimmermann Purinergic signalling in the nervous system: an overview Trends Neurosci. 32 2009 19 29
3. R.A. Surprenant North, signaling at purinergic P2X receptors Annu. Rev. Physiol. 71 2009 333 359
4. G. Burnstock B.B. Fredholm R.A. North A. Verkhratsky The birth and postnatal development of purinergic signalling Acta Physiol. (Oxf.) 199 2010 93 147
5. B.S. Khakh R.A. North P2X receptors as cell-surface ATP sensors in health and disease Nature 442 2006 527 532
6. M.T. Young P2X receptors: dawn of the post-structure era Trends Biochem. Sci. 35 2010 83 90
7. L.E. Browne L.H. Jiang R.A. North New structure enlivens interest in P2X receptors Trends Pharmacol. Sci. 31 2010 229 237
8. R.J. Evans Structural interpretation of P2X receptor mutagenesis studies on drug action Br. J. Pharmacol. 161 2010 961 971
9. R.A. North Molecular physiology of P2X receptors Physiol. Rev. 82 2002 1013 1067
10. N.P. Barrera S.J. Ormond R.M. Henderson R.D. Murrell-Lagnado J.M. Edwardson Atomic force microscopy imaging demonstrates that P2X2 receptors are trimers but that P2X6 receptor subunits do not oligomerize J. Biol. Chem. 280 2005 10759 10765
11. S.J. Ormond N.P. Barrera O.S. Qureshi R.M. Henderson J.M. Edwardson R.D. Murrell-Lagnado An uncharged region within the N terminus of the P2X6 receptor inhibits its assembly and exit from the endoplasmic reticulum Mol. Pharmacol. 69 2006 1692 1700
12. V. Compan L. Ulmann O. Stelmashenko J. Chemin S. Chaumont F. Rassendren P2X2 and P2X5 subunits define a new heteromeric receptor with P2X7-like properties J. Neurosci. 32 2012 4284 4296
13. B.S. Khakh X.R. Bao C. Labarca H.A. Lester Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds Nat. Neurosci. 2 1999 322 330
14. A. Virginio F.A. MacKenzie R.A. Rassendren A. North Surprenant, pore dilation of neuronal P2X receptor channels Nat. Neurosci. 2 1999 315 321
15. M.F. Jarvis B.S. Khakh ATP-gated P2X cation-channels Neuropharmacology 56 2009 208 215
16. G. Burnstock C. Kennedy P2X receptors in health and disease Adv. Pharmacol. 61 2011 333 372
17. G. Burnstock Purinergic signalling and disorders of the central nervous system Nat. Rev. Drug Discov. 7 2008 575 590
18. Coddou Z. Yan T. Obsil J.P. Huidobro-Toro S.S. Stojilkovic Activation and regulation of purinergic P2X receptor channels Pharmacol. Rev. 63 2011 641 683
19. R.J. Evans C. Lewis G. Buell S. Valera R.A. North A. Surprenant Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors) Mol. Pharmacol. 48 1995 178 183
20. R. Volpini R.C. Mishra D.D. Kachare D. Dal Ben C. Lambertucci I. Antonini S. Vittori G. Marucci E. Sokolova A. Nistri G. Cristalli Adenine-based acyclic nucleotides as novel P2X3 receptor ligands J. Med. Chem. 52 2009 4596 4603
21. G. Virginio A. Robertson R.A. Surprenant North, trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors Mol. Pharmacol. 53 1998 969 973
22. D.S. Carter M. Alam H. Cai M.P. Dillon A.P. Ford J.R. Gever A. Jahangir C. Lin A.G. Moore P.J. Wagner Y. Zhai Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain Bioorg. Med. Chem. Lett. 19 2009 1628 1631
23. C. Lambertucci M. Sundukova D.D. Kachare D.S. Panmand D. Dal Ben M. Buccioni G. Marucci A. Marchenkova A. Thomas A. Nistri G. Cristalli R. Volpini Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists Eur. J. Med. Chem. 65C 2013 41 50
24. Y. Baqi R. Hausmann C. Rosefort J. Rettinger G. Schmalzing C.E. Müller Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor J. Med. Chem. 54 2011 817 830
25. L. Alcaraz A. Baxter J. Bent K. Bowers M. Braddock D. Cladingboel D. Donald M. Fagura M. Furber C. Laurent M. Lawson M. Mortimore M. McCormick N. Roberts M. Robertson Novel P2X7 receptor antagonists Bioorg. Med. Chem. Lett. 13 2003 4043 4046
26. P.G. Baraldi M. del Carmen Nunez A. Morelli S. Falzoni F. Di Virgilio R. Romagnoli Synthesis and biological activity of N -arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor J. Med. Chem. 46 2003 1318 1329
27. J. Baxter K. Bent M. Bowers S. Braddock M. Brough M. Fagura T. Lawson M. McInally M. Mortimore R. Robertson P. Weaver Webborn Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists Bioorg. Med. Chem. Lett. 13 2003 4047 4050
28. P. Honore D. Donnelly-Roberts M.T. Namovic G. Hsieh C.Z. Zhu J.P. Mikusa G. Hernandez C. Zhong D.M. Gauvin P. Chandran R. Harris A.P. Medrano W. Carroll K. Marsh J.P. Sullivan C.R. Faltynek M.F. Jarvis A-740003 [ N -(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat J. Pharmacol. Exp. Ther. 319 2006 1376 1385
29. A.D. Michel M. Xing K.M. Thompson C.A. Jones P.P. Humphrey Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors Eur. J. Pharmacol. 534 2006 19 29
30. D.W. Nelson R.J. Gregg M.E. Kort A. Perez-Medrano E.A. Voight Y. Wang G. Grayson M.T. Namovic D.L. Donnelly-Roberts W. Niforatos P. Honore M.F. Jarvis C.R. Faltynek W.A. Carroll Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists J. Med. Chem. 49 2006 3659 3666
31. L. Stokes L.H. Jiang L. Alcaraz J. Bent K. Bowers M. Fagura M. Furber M. Mortimore M. Lawson J. Theaker C. Laurent M. Braddock A. Surprenant Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373 Br. J. Pharmacol. 149 2006 880 887
32. W.A. Carroll D.M. Kalvin A. Perez Medrano A.S. Florjancic Y. Wang D.L. Donnelly-Roberts M.T. Namovic G. Grayson P. Honore M.F. Jarvis Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists Bioorg. Med. Chem. Lett. 17 2007 4044 4048
33. P. Betschmann B. Bettencourt D. Donnelly-Roberts M. Friedman J. George G. Hirst N. Josephsohn D. Konopacki B. Li J. Maull M.J. Morytko N.S. Moore M. Namovic P. Rafferty J.A. Salmeron-Garcia E. Tarcsa L. Wang K. Woller Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists Bioorg. Med. Chem. Lett. 18 2008 3848 3851
34. A.S. Florjancic S. Peddi A. Perez-Medrano B. Li M.T. Namovic G. Grayson D.L. Donnelly-Roberts M.F. Jarvis W.A. Carroll Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)- N -(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)- N -(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists Bioorg. Med. Chem. Lett. 18 2008 2089 2092
35. M.J. Morytko P. Betschmann K. Woller A. Ericsson H. Chen D.L. Donnelly-Roberts M.T. Namovic M.F. Jarvis W.A. Carroll P. Rafferty Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)- N -o-tolylpiperazine-1-carboximidamide P2X7 antagonists Bioorg. Med. Chem. Lett. 18 2008 2093 2096
36. D.W. Nelson K. Sarris D.M. Kalvin M.T. Namovic G. Grayson D.L. Donnelly-Roberts R. Harris P. Honore M.F. Jarvis C.R. Faltynek W.A. Carroll Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists J. Med. Chem. 51 2008 3030 3034
37. D.L. Donnelly-Roberts M.T. Namovic B. Surber S.X. Vaidyanathan A. Perez-Medrano Y. Wang W.A. Carroll M.F. Jarvis [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors Neuropharmacology 56 2009 223 229
38. P. Honore D. Donnelly-Roberts M. Namovic C. Zhong C. Wade P. Chandran C. Zhu W. Carroll A. Perez-Medrano Y. Iwakura M.F. Jarvis The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice Behav. Brain Res. 204 2009 77 81
39. T. Kawate J.C. Michel W.T. Birdsong E. Gouaux Crystal structure of the ATP-gated P2X4 ion channel in the closed state Nature 460 2009 592 598
40. M. Hattori E. Gouaux Molecular mechanism of ATP binding and ion channel activation in P2X receptors Nature 485 2012 207 212
41. T. Chataigneau D. Lemoine T. Grutter Exploring the ATP-binding site of P2X receptors Front. Cell. Neurosci. 7 2013 273
42. S. Ennion S. Hagan R.J. Evans The role of positively charged amino acids in ATP recognition by human P2X(1) receptors J. Biol. Chem. 275 2000 29361 29367
43. L.H. Jiang F. Rassendren A. Surprenant R.A. North Identification of amino acid residues contributing to the ATP-binding site of a purinergic P2X receptor J. Biol. Chem. 275 2000 34190 34196
44. J.A. Roberts R.J. Evans ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists J. Biol. Chem. 279 2004 9043 9055
45. Z. Yan Z. Liang M. Tomic T. Obsil S.S. Stojilkovic Molecular determinants of the agonist binding domain of a P2X receptor channel Mol. Pharmacol. 67 2005 1078 1088
46. H. Zemkova Z. Yan Z. Liang I. Jelinkova M. Tomic S.S. Stojilkovic Role of aromatic and charged ectodomain residues in the P2X(4) receptor functions J. Neurochem. 102 2007 1139 1150
47. J.A. Roberts H.R. Digby M. Kara S. El Ajouz M.J. Sutcliffe R.J. Evans Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors J. Biol. Chem. 283 2008 20126 20136
48. M. Bodnar H. Wang T. Riedel S. Hintze E. Kato G. Fallah H. Groger-Arndt R. Giniatullin M. Grohmann R. Hausmann G. Schmalzing P. Illes P. Rubini Amino acid residues constituting the agonist binding site of the human P2X3 receptor J. Biol. Chem. 286 2011 2739 2749
49. R.C. Allsopp S. El Ajouz R. Schmid R.J. Evans Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating J. Biol. Chem. 286 2011 29207 29217
50. C. Wolf C. Rosefort G. Fallah M.U. Kassack A. Hamacher M. Bodnar H. Wang P. Illes A. Kless G. Bahrenberg G. Schmalzing R. Hausmann Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking Mol. Pharmacol. 79 2011 649 661
51. W.J. Wilkinson L.H. Jiang A. Surprenant R.A. North Role of ectodomain lysines in the subunits of the heteromeric P2X2/3 receptor Mol. Pharmacol. 70 2006 1159 1163
52. R. Jiang D. Lemoine A. Martz A. Taly S. Gonin L. Prado de Carvalho A. Specht T. Grutter Agonist trapped in ATP-binding sites of the P2X2 receptor Proc. Natl. Acad. Sci. U. S. A. 108 2011 9066 9071
53. W. Fischer Z. Zadori Y. Kullnick H. Groger-Arndt H. Franke K. Wirkner P. Illes P.P. Mager Conserved lysin and arginin residues in the extracellular loop of P2X(3) receptors are involved in agonist binding Eur. J. Pharmacol. 576 2007 7 17
54. J.A. Roberts R.J. Evans Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP J. Neurochem. 96 2006 843 852
55. J.A. Roberts M. Valente R.C. Allsopp D. Watt R.J. Evans Contribution of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis J. Neurochem. 109 2009 1042 1052
56. R.A. Worthington M.L. Smart B.J. Gu D.A. Williams S. Petrou J.S. Wiley J.A. Barden Point mutations confer loss of ATP-induced human P2X(7) receptor function FEBS Lett. 512 2002 43 46
57. J.A. Roberts R.J. Evans Cysteine substitution mutants give structural insight and identify ATP binding and activation sites at P2X receptors J. Neurosci. 27 2007 4072 4082
58. R. Hausmann J. Gunther A. Kless D. Kuhlmann M.U. Kassack G. Bahrenberg F. Markwardt G. Schmalzing Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor Mol. Pharmacol. 83 2013 73 84
59. J. Dundas Z. Ouyang J. Tseng A. Binkowski Y. Turpaz J. Liang CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues Nucleic Acids Res. 34 2006 116 118
60. Dal Ben I. Antonini M. Buccioni C. Lambertucci G. Marucci S. Vittori R. Volpini G. Cristalli Molecular modeling studies on the human neuropeptide S receptor and its antagonists ChemMedChem 5 2010 371 383
61. D. Sehnal R. Svobodova Varekova K. Berka L. Pravda V. Navratilova P. Banas C.M. Ionescu M. Otyepka J. Koca MOLE 2.0: advanced approach for analysis of biomacromolecular channels J. Cheminform 5 2013 39
62. J.M. Zimmerman N. Eliezer R. Simha The characterization of amino acid sequences in proteins by statistical methods J. Theor. Biol. 21 1968 170 201
63. J. Kyte R.F. Doolittle A simple method for displaying the hydropathic character of a protein J. Mol. Biol. 157 1982 105 132
64. D.J. Abraham A.J. Leo Extension of the fragment method to calculate amino acid zwitterion and side chain partition coefficients Proteins 2 1987 130 152
65. H.R. Guy Amino acid side-chain partition energies and distribution of residues in soluble proteins Biophys. J. 47 1985 61 70
66. R. Cowan R.G. Whittaker Hydrophobicity indices for amino acid residues as determined by high-performance liquid chromatography Pept. Res. 3 1990 75 80
67. J.L. Fauchere V. Pliska Hydrophobic parameters pi of amino acid side chains from partitioning of N -acetyl-amino-acid amides Eur. J. Med. Chem. 18 1983 369 375
68. S.S. Wildman S.G. Brown M. Rahman C.A. Noel L. Churchill G. Burnstock R.J. Unwin B.F. King Sensitization by extracellular Ca(2+) of rat P2X(5) receptor and its pharmacological properties compared with rat P2X(1) Mol. Pharmacol. 62 2002 957 966
69. B.R. Bianchi K.J. Lynch E. Touma W. Niforatos E.C. Burgard K.M. Alexander H.S. Park H. Yu R. Metzger E. Kowaluk M.F. Jarvis T. van Biesen Pharmacological characterization of recombinant human and rat P2X receptor subtypes Eur. J. Pharmacol. 376 1999 127 138
70. 2 receptors Mol. Pharmacol. 56 1999 1171 1181
71. M. Garcia-Guzman W. Stühmer F. Soto Molecular characterization and pharmacological properties of the human P2X3 purinoceptor Mol. Brain Res. 47 1997 59 66
72. X. Bo L.H. Jiang H.L. Wilson M. Kim G. Burnstock A. Surprenant R.A. North Pharmacological and biophysical properties of the human P2X5 receptor Mol. Pharmacol. 63 2003 1407 1416
73. F. Surprenant E. Rassendren R.A. Kawashima G. North Buell, the cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7) Science 272 1996 735 738
74. 3 allosteric modulator, cibacron blue Br. J. Pharmacol. 132 2001 259 269
75. M.L. He H. Zemkova S.S. Stojilkovic Dependence of purinergic P2X receptor activity on ectodomain structure J. Biol. Chem. 278 2003 10182 10188
76. D.L. Donnelly-Roberts M.T. Namovic P. Han M.F. Jarvis Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors Br. J. Pharmacol. 157 2009 1203 1214
77. M. Murgia S. Hanau P. Pizzo M. Rippa F. Di Virgilio Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor J. Biol. Chem. 268 1993 8199 8203
78. J.S. Wiley J.R. Chen M.B. Snook G.P. Jamieson The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP Br. J. Pharmacol. 112 1994 946 950
79. 7 receptor orthologs J. Pharmacol. Exp. Ther. 296 2001 947 957
80. Di Virgilio Novel data point to a broader mechanism of action of oxidized ATP: the P2X7 receptor is not the only target Br. J. Pharmacol. 140 2003 441 443
81. R.A. North A. Surprenant Pharmacology of cloned P2X receptors Annu. Rev. Pharmacol. Toxicol. 40 2000 563 580
82. T. Watanabe G. Inesi The use of 2',3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate for studies of nucleotide interaction with sarcoplasmic reticulum vesicles J. Biol. Chem. 257 1982 11510 11516
83. B.G. Mockett G.D. Housley P.R. Thorne Fluorescence imaging of extracellular purinergic receptor sites and putative ecto-ATPase sites on isolated cochlear hair cells J. Neurosci. 14 1994 6992 7007
84. C.J. Lewis A. Surprenant R.J. Evans 2',3'-O-(2,4,6- trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP)-a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels Br. J. Pharmacol. 124 1998 1463 1466
85. M. Hulsmann P. Nickel M. Kassack G. Schmalzing G. Lambrecht F. Markwardt NF449, a novel picomolar potency antagonist at human P2X1 receptors Eur. J. Pharmacol. 470 2003 1 7
86. K. Braun J. Rettinger M. Ganso M. Kassack C. Hildebrandt H. Ullmann P. Nickel G. Schmalzing G. Lambrecht NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors Naunyn Schmiedeb. Arch. Pharmacol. 364 2001 285 290
87. M.U. Kassack K. Braun M. Ganso H. Ullmann P. Nickel B. Boing G. Muller G. Lambrecht Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist Eur. J. Med. Chem. 39 2004 345 357
88. J. Rettinger K. Braun H. Hochmann M.U. Kassack H. Ullmann P. Nickel G. Schmalzing G. Lambrecht Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist Neuropharmacology 48 2005 461 468
89. R. Hausmann J. Rettinger Z. Gerevich S. Meis M.U. Kassack P. Illes G. Lambrecht G. Schmalzing The suramin analog 4,4',4',4'-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups Mol. Pharmacol. 69 2006 2058 2067
90. Soto G. Lambrecht P. Nickel W. Stuhmer A.E. Busch Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors Neuropharmacology 38 1999 141 149
91. M. Klapperstuck C. Buttner P. Nickel G. Schmalzing G. Lambrecht F. Markwardt Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors Eur. J. Pharmacol. 387 2000 245 252
92. J. Rettinger G. Schmalzing S. Damer G. Muller P. Nickel G. Lambrecht The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor Neuropharmacology 39 2000 2044 2053
93. M.F. Jarvis E.C. Burgard S. McGaraughty P. Honore K. Lynch T.J. Brennan A. Subieta T. Van Biesen J. Cartmell B. Bianchi W. Niforatos K. Kage H. Yu J. Mikusa C.T. Wismer C.Z. Zhu K. Chu C.H. Lee A.O. Stewart J. Polakowski B.F. Cox E. Kowaluk M. Williams J. Sullivan C. Faltynek A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat Proc. Natl. Acad. Sci. U. S. A. 99 2002 17179 17184
94. M.F. Jarvis B. Bianchi J.T. Uchic J. Cartmell C.H. Lee M. Williams C. Faltynek [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors J. Pharmacol. Exp. Ther. 310 2004 407 416
95. L.H. Jiang A.B. Mackenzie R.A. North A. Surprenant Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors Mol. Pharmacol. 58 2000 82 88
96. C.E. Gargett J.S. Wiley The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes Br. J. Pharmacol. 120 1997 1483 1490
97. Molecular Operating Environment, C.C.G., Inc., 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3.
98. J.J. Stewart MOPAC: a semiempirical molecular orbital program J. Comput. Aided Mol. Des. 4 1990 1 105
99. W.D. Cornell P. Cieplak C.I. Bayly I.R. Gould K.M. Merz D.M. Ferguson D.C. Spellmeyer T. Fox J.W. Caldwell P.A. Kollman A second generation force field for the simulation of proteins, nucleic acids, and organic molecules J. Am. Chem. Soc. 117 1995 5179 5197
100. T.A. Halgren Merck molecular force field. I. basis, form, scope, parameterization, and performance of MMFF94 J. Comput. Chem. 17 1996 490 519
101. T.A. Halgren Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions J. Comput. Chem. 17 1996 520 552
102. T.A. Halgren Merck molecular force field. III. molecular geometries and vibrational frequencies for MMFF94 J. Comput. Chem. 17 1996 553 586
103. T.A. Halgren Merck molecular force field. IV. conformational energies and geometries for MMFF94 J. Comput. Chem. 17 1996 587 615
104. T.A. Halgren R. Nachbar Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules J. Comput. Chem. 17 1996 616 641
105. T.A. Halgren MMFF VI. MMFF94s option for energy minimization studies J. Comput. Chem. 20 1999 720 729
106. T.A. Halgren MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries J. Comput. Chem. 20 1999 730 748